stockrow
Saturday 7 November 2026
Export FLNA’s income statement to Excel — free account
Cassava Sciences, Inc.
FLNA Healthcare Biotechnology
- EPS
- +80.4%
- Free cash flow
- +21.7%
Quarter to June 2026, against a year earlier
0.45
0.00
0.00%
Follow FLNA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | 41 | — | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (15) | (12) | (7) | (5) | (6) | (32) | (76) | (97) | (24) | (91) | (42) | +22.3% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (15) | (12) | (7) | (5) | (6) | (32) | (76) | (97) | (24) | (91) | (42) | +22.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (2.31) | (1.82) | (0.61) | (0.27) | (0.24) | (0.82) | (1.90) | (2.32) | (0.53) | (1.88) | (0.87) | (2.3%) | ||||||
| Cash flow | (1.88) | (1.26) | (0.45) | (0.14) | (0.21) | (0.77) | (1.93) | (1.96) | (2.52) | (0.67) | (0.59) | (10.8%) | ||||||
| Capex | (0.01) | 0.00 | 0.00 | 0.00 | 0.01 | (0.56) | (0.07) | (0.01) | 0.00 | (0.01) | (0.01) | +0.5% | ||||||
| Free cash flow | (1.89) | (1.26) | (0.45) | (0.15) | (0.19) | (1.33) | (2.00) | (1.97) | (2.53) | (0.68) | (0.61) | (10.7%) | ||||||
| Book value | 2.86 | 1.48 | 1.84 | 1.27 | 3.53 | 6.44 | 5.66 | 3.28 | 3.15 | 1.54 | 1.32 | (6.6%) | ||||||
| Shares, m | 7 | 7 | 11 | 17 | 26 | 39 | 40 | 42 | 46 | 48 | 48 | +24.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (12) | (8) | (5) | (3) | (5) | (30) | (78) | (82) | (117) | (32) | (29) | +11.4% | |||||
| Capex | 0 | — | — | 0 | 0 | (22) | (3) | 0 | 0 | (1) | (1) | +25.5% | ||||||
| Free cash flow | (12) | (8) | (5) | (3) | (5) | (52) | (80) | (82) | (117) | (33) | (29) | +11.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 18 | 10 | 20 | 22 | 92 | 232 | 204 | 115 | 125 | 54 | 44 | +12.7% | |||||
| Net debt | (19) | (10) | (20) | (23) | (94) | (233) | (201) | (121) | (129) | (96) | (83) | +19.9% | ||||||
| Shareholders’ equity | 19 | 10 | 20 | 22 | 92 | 254 | 228 | 137 | 146 | 74 | 64 | +16.6% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (57.99) | (79.06) | (42.34) | (21.23) | (10.76) | (17.94) | (30.40) | (50.31) | (15.75) | (65.95) | (35.34) | (8.0) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (100.31) | (188.56) | (405.48) | (516.08) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (61.87) | (84.07) | (44.72) | (22.20) | (11.08) | (18.71) | (31.67) | (53.27) | (17.19) | (82.66) | (55.78) | (20.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 9 | 9 | 9 | 9 | 11 | 24 | 26 | 29 | 30 | 17 | — | +7.3% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2013 · latest quarter Dec 2013 · fundamentals updated 26 Oct 2026
Cassava Sciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CELU Celularity, Inc. | $23.5M | — (loss-making) | — (loss-making) | −5.30% (below 0%: shrinking) | n/m | −10.91% (below 0%: shrinking) | 56.79% | (78.00%) | Compare |
| NXTC NextCure, Inc. | $23.4M | — (loss-making) | — (loss-making) | +1,549.08% (above 0%: growing) | n/m | +57.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| EVAX Evaxion A/S - Sponsored ADR | $23.0M | — (loss-making) | — (loss-making) | +14,590.20% (above 0%: growing) | n/m | −56.70% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IGC IGC Pharma, Inc. | $22.0M | — (loss-making) | — (loss-making) | 0.00% | n/m | −45.33% (below 0%: shrinking) | 18.60% | (588.72%) | Compare |
| CRVO CervoMed Inc. | $21.9M | — (loss-making) | — (loss-making) | −99.60% (below 0%: shrinking) | n/m | −6.20% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| FLNA Cassava Sciences, Inc. | $21.8M | — (loss-making) | — | +1,328.04% (above 0%: growing) | n/m | +21.65% (above 0%: growing) | 0.00% | 0.00% | |
| MCRB Seres Therapeutics, Inc. | $20.8M | — (loss-making) | — (loss-making) | +68.95% (above 0%: growing) | n/m | −576.66% (below 0%: shrinking) | 100.00% | (2,723.78%) | Compare |
| ATOS Atossa Therapeutics, Inc. | $20.2M | — (loss-making) | — | −94.28% (below 0%: shrinking) | n/m | −32.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IMMP Prima BioMed Ltd | $19.8M | — | — | — | n/m | −589,653.13% (below 0%: shrinking) | 100.00% | (101.89%) | Compare |
| Median of peers | $21.9M | — | — | 0.00% | — | −39.09% | 78.39% | (39.00%) |
Pay and ownership Proxy statement filed 28 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.52m | 1.33m | 6.70 |
Ownership
Directors and executive officers, together
4.60%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement